Skip to content
HowShorted

PMV Pharmaceuticals, Inc. short interest in 2022

In 2022, PMV Pharmaceuticals, Inc.'s disclosed short interest ran from 10.63% of shares outstanding on 14 Jan 2022 to 20.78% on 30 Dec 2022, a change of +10.15 percentage points. The year's high was 31.56% on 15 Jul 2022 and its low 10.63% on 14 Jan 2022, averaging 22.93% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 26.64 days on 14 Oct 2022. Full history: PMV Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for PMV Pharmaceuticals, Inc. in 2022

2022 in figures

Start of year
10.63% (14 Jan 2022)
End of year
20.78% (30 Dec 2022)
Change
+10.15 pp
High
31.56% (15 Jul 2022)
Low
10.63% (14 Jan 2022)
Average
22.93%
Highest days to cover
26.64 (14 Oct 2022)
SEC filings marked
8

Every report in 2022

PMV Pharmaceuticals, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 202210.63%5.55
31 Jan 202212.10%9.86
15 Feb 202215.27%6.99
28 Feb 202216.92%9.10
15 Mar 202218.16%15.6910-K filed, results (8-K)
31 Mar 202217.57%9.33
14 Apr 202217.11%8.67
29 Apr 202221.09%8.46
13 May 202225.34%10.4510-Q filed, results (8-K)
31 May 202226.98%5.31
15 Jun 202226.65%4.68
30 Jun 202230.05%6.20
15 Jul 202231.56%17.25
29 Jul 202230.21%24.12
15 Aug 202229.58%20.4910-Q filed, results (8-K)
31 Aug 202228.68%22.92
15 Sep 202228.77%16.08
30 Sep 202226.86%15.15
14 Oct 202225.85%26.64
31 Oct 202225.29%23.84
15 Nov 202222.90%15.2710-Q filed, results (8-K)
30 Nov 202221.60%20.56
15 Dec 202220.39%17.44
30 Dec 202220.78%15.93

See also: PMV Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.